Topic

Ira Studin, PhD, MPH, is president of Stellar Managed Care Consulting, a pharma busines strategies firm in Cherry Hill, New Jersey. He has written Strategic Healthcare Management and numerous articles in healthcare business journals. He can be reached at istudin@stellarmc.com

Articles

Emerging limits of one-year payer time frames.

Could Time Be the Next New Element in Pharma Revenue?

Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of the Oncology Strategic Business Unit

Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.

When Innovation Outpaces HTA, Access Struggles to Keep Up

Accreditation Council for Medical Affairs (ACMA)

Faster launch planning leads to greater access.

How Medical Affairs Can Contribute to Successful Drug Launch

Neil Grubert is a global market access consultant.

The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.

A Brave New World: Optimizing Access in Wake of COVID

Examining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.

By Any Genes Necessary: The Role of MEAs for Gene Therapies

The BCG Market Access Roundtable presents an updated view of its access competencies framework first published five years ago.

A Framework for Future: Strengthening Market Access Competencies

A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.

Value Risk and Reward: Taking Stock of Value-Based Contracts in Pharma

 is a partner in Guidehouse’s Life Sciences practice. Chance is the practice lead for Guidehouse's Market Access Center of Excellence for the pharmaceutical segment. Chance works with clients to develop comprehensive access strategies across pricing, value proposition development, and coding / reimbursement policy.

Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.

Evolve the Role of Reimbursement Policy to Meet the Needs of the New Market Access Ecosystem

Chairman, CEO, Accreditation Council for Medical Affairs

A focus on medical affairs and medical science liaisons.

The Foundations of Pharmaceutical Industry Compliance

Pandemic-reinforced principles of successful drug launch.